Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 3/20 | 0.32 |
| ▸ | TLR2 | O60603 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036698 | 0.94 | CA12 (0.40) | HSD11B1CA12CA1CA2CA4 | |
| SCHEMBL21036704 | 0.91 | HSD11B1 (0.36) | HSD11B1CA12CA1CA2CA4 | |
| SCHEMBL21036694 | 0.86 | TLR4 (0.36) | HSD11B1CA12CA1CA2CA4 | |
| SCHEMBL22732938 | 0.86 | CA12 (0.39) | HSD11B1CA12CA1CA2CA4 | |
| SCHEMBL21036617 | 0.85 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL21036695 | 0.85 | HSD11B1 (0.41) | HSD11B1CHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL21036620 | 0.83 | PTGS2 (0.34) | HSD11B1CHRNB2CHRNA4 | |
| SCHEMBL21036702 | 0.83 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL25799587 | 0.81 | GRIN1 (0.39) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL21036706 | 0.81 | CA12 (0.41) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021231582-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF NEGATIVE SYMPTOMS AND COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | EUMENTIS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021188864-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20200377444-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019104020-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377444-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | NLN, SLC1A2, AANAT | HSD11B1 1331/4885CA12 1324/4885CA1 1320/4885 |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | NLN, SLC1A2, AANAT | HSD11B1 1331/4885CA12 1324/4885CA1 1320/4885 |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | ACE2, ACE, MME | HSD11B1 14/4885CA12 1135/4885CA1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.